3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Breast
1
Conditions
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
NSCLC
1
Mesothelioma
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Small Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
30
Nivolumab
12
Carboplatin
6
atezolizumab
5
Trastuzumab
5
aldesleukin
4
Specimen Handling
4
Paclitaxel
4
Magnetic Resonance Spectroscopy
4
Ipilimumab
4
Docetaxel
4
Cyclophosphamide
4
Cisplatin
4
Bevacizumab
4
spartalizumab
3
fludarabine
3
durvalumab
3
Polymerase Chain Reaction
3
Irinotecan
3
Interleukin-2
3
Gene Expression Profiling
3
Blood Specimen Collection
3
Biopsy
3
zimberelimab
2
tisotumab vedotin
2
tislelizumab
2
sargramostim
2
osimertinib
2
enzalutamide
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Diphenhydramine
×
Thoracic
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled